Vanda Q4 Loss of $0.46 Beats Estimates by 78.9%, Revenue Misses by 2.8%
Vanda reported a Q4 adjusted loss of $0.46 per share, outperforming the $2.18 loss estimate by 78.9% and against a prior-year loss of $0.08. Revenue was $57.2 million, 2.8% below the $58.9 million consensus, while shares have slid roughly 15.9% year-to-date.
1. Q4 Financial Results
Vanda reported an adjusted EPS loss of $0.46 in the fourth quarter, surpassing the consensus estimate of a $2.18 loss by 78.9% and compared with a $0.08 loss in the year-ago period. Total revenues reached $57.22 million, missing the $58.9 million consensus by 2.78%.
2. Stock Performance
Shares of Vanda have declined about 15.9% since the start of the year, underperforming the S&P 500’s 1.4% gain over the same period. The company operates within the Medical - Biomedical and Genetics industry, where it ranks in the top 35% among peers.
3. Outlook and Analyst Expectations
Analysts project a first-quarter loss of $0.24 per share on $64 million in revenue and a full-year loss of $1.47 on $275.85 million in revenue. Future stock momentum will hinge on management commentary and upcoming revisions to earnings and revenue estimates.